Singapore-based Prestige BioPharma has entered into 2 new agreements related to its proposed biosimilar trastuzumab, HD201, which it hopes to sell under the brand name Tuznue.
Singapore-based Prestige BioPharma has entered into 2 new agreements related to its proposed biosimilar trastuzumab, HD201, which it hopes to sell under the brand name Tuznue.
The company announced today that it has entered into an exclusive agreement with Pharmapark LLC to supply and commercialize the biosimilar in Russia. Pharmapark, a privately owned Russian pharmaceutical company, currently markets 5 biosimilars in Russia.
The company’s chief executive officer (CEO), Visily Skrypin, said in a statement that Pharmapark looks forward to the opportunity to bring the new product to the market to provide safe and effective treatment for Russian patients who have HER2-positive cancers.
The deal with Pharmapark comes shortly after Mundipharma announced that it had entered into an exclusive license and supply agreement with Prestige to sell the biosimilar in parts of Europe.
The agreement will allow Mundipharma, a network of independent companies that operates in 120 countries worldwide and distributes a number of biosimilars in the European Union, to sell the biosimilar trastuzumab in countries including France, Spain, Norway, Sweden, Denmark, Finland, Portugal, Switzerland, and Austria after the product’s expected authorization by the European Commission.
In a statement announcing the deal, Lisa S. Park, PhD, CEO of Prestige, said, “We are very pleased to partner with Mundipharma to commercialize our lead biosimilar in the selected European markets. This partnership is an important milestone for Prestige BioPharma, which will further increase the global availability of our trastuzumab biosimilar so that more patients can benefit from its quality and accessibility.” She added that companies see a potential for future expansion of their partnership.
The newly announced agreements are just the latest in a string of deals concerning the biosimilar for Prestige; in late 2018, Prestige announced that it had entered into a licensing agreement with Cipla Limited to distribute and market the biosimilar trastuzumab in some emerging markets. Earlier, Prestige announced a deal with Alvogen to commercialize the biosimilar in Central and Eastern Europe.
The proposed biosimilar is currently under review by the European Medicines Agency, and Prestige has also indicated that it plans to file an application for the biosimilar with the FDA in 2019.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.